Logotype for Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals (BOT) Q1 2027 TU earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Botanix Pharmaceuticals Limited

Q1 2027 TU earnings summary

27 Oct, 2026

Executive summary

  • Sofdra shipments rose 5.3% QoQ to 35,130, while Q1 FY27 net revenue remained $10.1m and operating cash outflow fell 13% to $9.225m.

  • October cost actions target ~50% lower operating expenses for the rest of FY27, with an estimated ~75% of revenue-generating ability retained; this is not a revenue forecast.

  • Priorities include maximizing Sofdra revenue, global licensing and commercialization, complementary in-licensing, revised debt terms and evaluating broader transaction alternatives.

Financial highlights

  • Q1 FY27 Sofdra gross sales rose to $49.3m from $46.7m QoQ, while unaudited net revenue remained $10.1m.

  • Quarter-end cash and cash equivalents were $24.358m, down from $36.631m; inventory was ~$30.8m versus $31.3m in Q4 FY26.

  • Product-sales receipts increased 13% QoQ to $15.161m; net operating cash outflow declined to $9.225m from $10.6m.

  • Operating costs were $11.313m, down 1% QoQ, while manufacturing costs fell 35% to $0.8m from $1.2m.

Outlook and guidance

  • October actions target ~50% lower operating expenses for the remainder of FY27 versus Q1 FY27, with ~60% headcount reduction and estimated retention of ~75% of revenue-generating ability.

  • Remaining FY27 assumptions include ~$2m manufacturing costs, operating and staff costs flat, G&A flat, and gross-to-net payments tracking product sales.

  • Management expects gross-to-net improvement in Q2 FY27 if other factors remain constant; the annual US insurance deductible reset is expected to weigh temporarily on Q3 FY27 GTN.

  • Piramal API technology transfer is expected to reduce cost of goods sold by 25%–40%; completing the process is a priority.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Botanix Pharmaceuticals